There is growing recognition that B cell contributions to normal immune responses extend
well beyond their potential to become antibody-producing cells, including roles at the innate …

The disruption of blood–brain barrier (BBB) for multiple sclerosis (MS) pathogenesis has a
double effect: early on during the onset of the immune attack and later for the CNS self …

Dimethyl fumarate (DMF) is an effective treatment option for relapsing–remitting multiple
sclerosis (MS), but its therapeutic mechanism of action has not been fully elucidated. A …

The cause and the pathogenic mechanisms leading to multiple sclerosis (MS), a chronic
inflammatory disease of the central nervous system (CNS), are still under scrutiny. During …

Anti-CD20 therapy to deplete B cells is highly efficacious in preventing new white matter
lesions in patients with relapsing-remitting multiple sclerosis (RRMS), but its protective …

In 1997, rituximab was the first monoclonal antibody clinically approved for the treatment of
cancer. Ten years later, progressive multifocal leukoencephalopathy (PML), until that time a …

Abstract IL-17-producing CD8+ (Tc17) cells are enriched in active lesions of patients with
multiple sclerosis (MS), suggesting a role in the pathogenesis of autoimmunity. Here we …

Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous
system (CNS) in which demyelination and neurodegeneration occurs. The immune system …

Fumaric acid ester-based drugs are used for the treatment of psoriasis and multiple
sclerosis. All licensed fumaric acid ester drugs contain dimethylfumarate (DMF) as the main …

Objective To assess functional changes in lymphocyte repertoire and subsequent clinical
implications during delayed-release dimethyl fumarate (DMF) treatment in patients with …